Versant Venture Capital VI, L.P. sold LENZ
September 30, 2025 · Form 4 insider transaction
Versant Venture Capital VI, L.P. sold 83,066 shares of LENZ Therapeutics, Inc. at $46.41 per share, a transaction worth $3.85M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.; These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.